Drugmaker Merck said Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with President Trump’s tariffs. The new facility will produce ...

April 29 (Reuters) - U.S. drugmaker Merck (MRK.N), opens new tab said on Tuesday it is investing $1 billion in a new Delaware plant to expand domestic production as it prepares to deal with ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US and China. The estimate doesn’t account for the possibility that ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed ...

Merck (MRK) released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA is reviewing the application for approval. The data showed that ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial hypertension functional class II or III at intermediate or ...

The image on this article has be replaced with one that depicts the accurate Merck logo. Investopedia requires writers to use primary sources to support their work. These include white papers ...

Merck Foundation (www.Merck-Foundation.com), the philanthropic arm of Merck KGaA Germany announced the Winners of Merck Foundation Africa Media Recognition “More Than a Mother” Awards 2023 and ...

KIRKLAND, QC, Feb. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, has entered into a multi-year agreement with the Vector Institute in Toronto, an ...

By Rebecca Robbins The pharmaceutical company Merck sued the government on Tuesday over a federal law that empowers Medicare for the first time to negotiate prices directly with drugmakers.

We believe that Merck stock (NYSE: MRK) is currently a better pick than its peer Eli Lilly stock (NYSE: LLY), given its comparatively lower valuation of 4.7x trailing revenues vs. 10.5x for Eli ...